Erythropoietin stimulating agents (ESAs) are pharmaceutical compounds designed to stimulate the production of red blood cells in the body. They find applications in various medical contexts, particularly in treating anemia associated with chronic kidney disease, cancer, and certain other conditions. ESAs offer the feature of enhancing haemoglobin levels, thereby improving oxygen-carrying capacity and alleviating fatigue and weakness in patients. Their use spans both primary and adjunctive treatments, contributing significantly to better quality of life and improved overall health outcomes.
According to Data Bridge Market Research, the Global Erythropoietin Stimulating Agents Market accounted for USD 14.46 billion by 2021 and is expected to reach USD 31.56 billion by 2029. The market is expected to grow with a CAGR of 10.25% in the forecast period of 2022 to 2029.
“Growing population of anemic patients boosts the market’s growth”
The growing population of anemic patients is a driving force behind the expansion of the erythropoietin stimulating agents (ESA) market. As anemia remains a prevalent concern, ESAs play a pivotal role in stimulating red blood cell production. With increasing awareness and diagnosis of anemia, the demand for these agents has surged. ESAs effectively address the underlying cause of anemia, enhancing patient quality of life and overall health. This rising demand for ESAs is contributing significantly to the market's growth trajectory.
What restraints the growth of the global erythropoietin stimulating agents market?
“Strict regulatory guidelines restraints the market’s growth”
The growth of the erythropoietin stimulating agents (ESA) market is hampered by strict regulatory guidelines. Regulatory bodies impose rigorous requirements due to safety concerns and potential adverse effects associated with ESAs. These guidelines necessitate extensive clinical trials, rigorous monitoring, and stringent labeling requirements. The process leads to prolonged approval timelines and increased development costs. While regulations ensure patient safety, they pose challenges to market expansion, affecting the speed and ease of bringing new ESA products to market.
Segmentation: Global Erythropoietin Stimulating Agents Market
The global erythropoietin stimulating agents market is segmented on the basis of product type and disease cured.
- On the basis of product type, the global erythropoietin stimulating agents market is segmented into epoetin-alfa, epoetin-beta, epoetin-omega, epoetin-delta, darbepoetin-alfa.
- On the basis of disease cured, the global erythropoietin stimulating agents market is segmented into oncology diseases, kidney disorders, anemia, neural disease, Wound Healing, antiretroviral treatment (art), cancer chemotherapy.
Regional Insights: North America dominates the Global Erythropoietin Stimulating Agents Market
North America dominates the erythropoietin stimulating agents market due to the increasing incidence of chronic ailments is compounded by the presence of numerous manufacturers in the area, leading to a complex healthcare landscape. This scenario highlights the challenges posed by the combination of growing chronic conditions and a diverse range of producers in the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to heightened awareness about health among the population is driving a surge in demand for cutting-edge medical technology. This trend reflects the increasing emphasis on health consciousness and the desire for innovative healthcare solutions to address evolving medical needs.
Recent Developments
- In September 2019, The Darbepoetin Alfa BS Injection JCR, developed as a long-acting erythropoiesis-stimulating agent, received approval in Japan through a collaborative effort by JCR Pharmaceuticals Co., Ltd. and Kissei Pharmaceutical Co., Ltd. The Phase III trial demonstrated that this new formulation exhibited comparable safety profiles and demonstrated equivalent efficacy and safety compared to the original Darbepoetin alpha (innovator product).
- In July 2020, PT Kalbe Genexine Biologics initiated a Phase III clinical trial for Efepoetin Alfa, intended to address anemia in individuals with chronic kidney disease who are not undergoing dialysis treatment.
- In February 2020, Samsung Medical Center initiated a Phase III clinical trial to investigate the effectiveness of Ferinject, an intravenous iron injection, in treating anemia among cancer patients. This multicenter randomized study focused on evaluating the efficacy of the treatment.
To know more about the study visit, https://www.databridgemarketresearch.com/reports/global-erythropoietin-stimulating-agents-market
The Prominent Key Players Operating in the Global Erythropoietin Stimulating Agents Market Include:
- Amgen Inc (U.S.)
- Biocon (India)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Thermo Fisher Scientific Inc. (U.S.)
- Hospira Inc. (U.S.)
- 3SBio Group (China)
- Celltrion Inc. (South Korea)
- Intas Pharmaceuticals Ltd. (India)
Above are the key players covered in the report, to know about more and exhaustive list of global erythropoietin stimulating agents market companies contact, https://www.databridgemarketresearch.com/contact
Research Methodology: Global Erythropoietin Stimulating Agents Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
